It’s a time of ordeal for brain function enhancers. In addition to choline alfoscerate, whose scope of use has been reduced through reimbursement reevaluations, acetyl-L-carnitine failed to demonstrate its efficacy during clinical reevaluations.

As a result, acetyl-L-carnitine is expected to completely disappear from the prescription market. Oxiracetam, which accounts for the third-largest share of the brain function enhancer market, is set to receive clinical reevaluations and reimbursement reevaluations soon. If oxiracetam also takes a blow, industry officials predict that the brain function enhancer market itself will greatly retract.

On the 5th, the Ministry of Food and Drug